by
Barbara Culliton
|
Editor’s Note: In an interview published this week, Health Affairs Contributing Editor Barbara Culliton asks Food and Drug Administration (FDA) Associate Commissioner For Science, Norris Alderson, about his agency’s regulation of nanomedicine and the potential for health care cost savings. Here’s an excerpt of their conversation: Barbara Culliton: Nanomedicine is the “next big thing” in [...]
by
Barbara Culliton
|
Last week, Health Affairs published three interviews [one-week free access] that I conducted with leading cancer oncologists. As Donald Kennedy, editor-in-chief of Science, and I wrote in an introduction to these interviews: “An intellectual chasm exists between those who do innovative research and those who deliver it. Researchers and physician-scientists read different journals than their counterparts in health policy [...]
by
Barbara Culliton
|
By any measure, heart disease, once manifest by sudden death, has largely joined the ranks of chronic diseases in developed countries that can be managed by drugs and behavior, as several articles in the new January-February issue of Health Affairs devoted to Cardiovascular Disease & Society note. And of all diseases that have been long-studied [...]
